Altomonte Lab

Research focus

ERC Starting Grant · 2019

A multifaceted cancer immunotherapy based on an immune checkpoint-modulating chimeric oncolytic virus vector in combination with a dendritic cell vaccine

Despite many decades of intensive research, cancer remains a major worldwide health concern and imposes a heavy societal burden, both epidemiologically and financially. Cancer immunotherapy is rapidly transforming the face of medical oncology as an exciting paradigm shift in treating cancer by exploiting the immune system of the patient as the basis for the therapy. Although dramatic results have been achieved in a subset of patients, the responses in most solid tumors have been disappointing. Hepatocellular carcinoma (HCC) represents a particularly challenging malignancy to treat, due to the inherently immune-suppressive microenvironment in the liver. Oncolytic viruses (OVs) offer an…

From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.